Biomarker-Targeted Therapies in Non-Small Cell Lung Cancer: Current Status and Perspectives

Haiyang Guo; Jun Zhang; Chao Qin; Hang Yan; Tao Liu; Haiyang Hu; Shengjie Tang; Shoujun Tang; Haining Zhou

doi:10.3390/cells11203200

Biomarker-Targeted Therapies in Non-Small Cell Lung Cancer: Current Status and Perspectives

Cells. 2022 Oct 12;11(20):3200. doi: 10.3390/cells11203200.

Authors

Haiyang Guo^{1

2}, Jun Zhang^{1

3}, Chao Qin^{1

3}, Hang Yan^{1

3}, Tao Liu^{1

3}, Haiyang Hu^{1

3}, Shengjie Tang¹, Shoujun Tang¹, Haining Zhou^{1

2

3}

Affiliations

¹ Department of Thoracic Surgery, Suining Central Hospital, Suining 629099, China.
² Institute of Surgery, Graduate School, Chengdu University of TCM, Chengdu 610075, China.
³ Institute of Surgery, Graduate School, Zunyi Medical University, Zunyi 563003, China.

Abstract

Non-small-cell lung cancer (NSCLC) is one of the most common malignancies and the leading causes of cancer-related death worldwide. Despite many therapeutic advances in the past decade, NSCLC remains an incurable disease for the majority of patients. Molecular targeted therapies and immunotherapies have significantly improved the prognosis of NSCLC. However, the vast majority of advanced NSCLC develop resistance to current therapies and eventually progress. In this review, we discuss current and potential therapies for NSCLC, focusing on targeted therapies and immunotherapies. We highlight the future role of metabolic therapies and combination therapies in NSCLC.

Keywords: immunotherapies; non-small-cell lung cancer; targeted therapies.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Biomarkers
Carcinoma, Non-Small-Cell Lung* / pathology
Humans
Immunotherapy
Lung Neoplasms* / drug therapy
Lung Neoplasms* / metabolism
Molecular Targeted Therapy

Substances

Biomarkers

Grants and funding

Chengdu University of Traditional Chinese Medicine: YYZX2020093.